Skip to main content

CASE REPORT article

Front. Oncol.
Sec. Cancer Molecular Targets and Therapeutics
Volume 14 - 2024 | doi: 10.3389/fonc.2024.1440379

Response to furmonertinib in a patient with non-small cell lung cancer harboring HER2 exon 21 insertion mutation: A case report

Provisionally accepted
Chunxiao Ni Chunxiao Ni 1Ling Zhang Ling Zhang 2Xin Yu Xin Yu 2Yu Pang Yu Pang 3Jiaju Xu Jiaju Xu 1*
  • 1 Department of Clinical Oncology, Taian City Central Hospital, Taian, China
  • 2 Tai'an City Central Hospital, Tai’an, Shandong, China
  • 3 Department of Pathology, Tai'an City Central Hospital, Tai'an, Shandong Province, China

The final, formatted version of the article will be published soon.

    Background: This is the first case report describing a patient with nonsmall cell lung cancer (NSCLC) harboring two rare human epidermal growth factor receptor 2 (HER2) exon 21 insertion mutations, who responded to furmonertinib treatment. Furmonertinib maybe one effective and economical treatment for NSCLC patients harboring HER2 mutations with minor side effects.Case Description: We present a case report of a 49-year-old female diagnosed with stage IV lung adenocarcinoma who complained of irritating dry cough symptoms followed by chest tightness. Firstly, we describe the patient's treatment history, including failed third-line combination treatments of systemic chemotherapy with bevacizumab or carrelizumab or anlotinib, primary lung tumor recurrence, bilateral lung metastases progression, and new brain metastatic lesion detection. Next, we detail the patient's fourth-line treatment with radiotherapy for brain metastases and two cycles of bevacizumab plus Abraxane and cisplatin, however, the disease progressed and relapsed. After that, comprehensive genomic profiling revealed two HER2 exon 21 insertion mutations.Subsequently, the patient received targeted therapy with furmonertinib and achieved 11 months of progression-free survival. The patient received pyrrotinib therapy for 2 months after disease progression, but the disease continued to progress. In October 2023, the patient received therapy with furmonertinib again, and a month later, the disease went into partial remission. However, the patient died due to hypoproteinemia combined with severe pneumonia in December 2023.Furmonertinib may be effective for NSCLC patients with HER2 T8962A and L869R mutations and further studies are needed to confirm these results in prospective clinical trials.

    Keywords: furmonertinib, Non-small cell lung cancer, HER2, Mutation, case report

    Received: 29 May 2024; Accepted: 10 Oct 2024.

    Copyright: © 2024 Ni, Zhang, Yu, Pang and Xu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Jiaju Xu, Department of Clinical Oncology, Taian City Central Hospital, Taian, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.